
Eurofins Discovery is a fully integrated drug discovery CRO, with more than 40 years of experience across chemistry, biology, ADME, pharmacology, safety, and toxicology, providing high-value, consultative approaches to drug discovery programs from Idea to IND enabled. Our cross-functional teams bring deep expertise in small and large molecule drug discovery, spanning core therapeutic areas, including (immune)-oncology, inflammation, neuroscience, metabolism, immunology, and infectious diseases.
The Vice President of Business Development Discovery Europe is responsible for defining and directing the business development strategy that builds the sales funnel that serves the global Eurofins Discovery sites and ultimately leads to closed /won that achieves the sales targets for the region. The role also contributes to the regional marketing strategy, ensuring alignment with marketing strategy and tactics and represents one face to the customer from global Eurofins Discovery companies. This role also is responsible for the regional Key Account / strategic account strategy and successful implementation.
Are you the person we are looking for? If so, please visit our web-site at https://careers.eurofins.com/uk/ for more information on how to apply quoting job reference EID/001/0526 The closing date for applications is Monday 11th June 2026.
Eurofins Scientific is an international life sciences company which provides a unique range of analytical testing services to clients across multiple industries. The Group believes it is the world leader in food, environmental and pharmaceutical products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and for supporting clinical studies. Eurofins is one of the key emerging players in speciality clinical diagnostic testing in Europe and the USA.
In 2025, Eurofins generated total revenues of €7.296 billion and has been among the best performing stocks in Europe over the past 20 years.

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories.
Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing.
Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.